United States · Biotechnology startup

Aktis Oncology

Aktis Oncology is a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals.

Funding reportedLast round: Corporate round

BiotechnologyBoston, United States

What company datasets say Aktis Oncology raised

Funding, as reported

Reported in all$175Min dollars
Rounds3
Last roundCorporate round
Last round dateMay 2024
Investors listed15
SEC Form D$175M sold, 1 filing, last Oct 2024

Founders and team

From Aktis Oncology's own website: 1 founder, 9 on the team.

Todd FoleyCo-founder and Chairman
  • Dana KennedySenior Vice President
  • Kyle KuvalankaChief Financial Officer
  • Mary ThistleIndependent Director
  • Mike ShermanIndependent Director
  • Carlos RodriguezTeam
  • Karen McCarthyTeam
  • Lorraine HorganTeam
  • Nate DemarsTeam
  • Timothy I. MitchellTeam

On 6 portfolio pages

Investors who name them

Each firm lists Aktis Oncology on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

Biotechnology in United States

Startups like it

Is this your company?

Add your raise, your deck and your story, and put Aktis Oncology in front of investors. Or tell us what we have wrong.

List your startupSend a correction